SS Innovations International Inc. (NASDAQ: SSII) announced record first-quarter 2026 financial results, with revenue reaching $11.1 million—a 116.8% increase year over year—highlighting the accelerating commercial adoption of its SSi Mantra surgical robotic platform. The company, a developer of innovative surgical robotic technologies for cardiac and other surgeries including telesurgeries, reported that gross profit rose to $5.3 million from $1.1 million in the same period last year, driven primarily by higher system installations and increased procedure volumes.
The installed base of SSi Mantra systems reached 194 across 11 countries, with nearly 9,750 cumulative robotic procedures completed by the end of the first quarter. As of June 22, 2026, that number had grown to 11,719 multi-specialty procedures, including 612 cardiac procedures, 175 telesurgeries, and 212 pediatric surgeries. Additionally, approximately 2,100 physicians have been trained on the system, which has been utilized for over 170 different types of procedures.
This news matters because it signals a significant shift in surgical robotics adoption beyond developed markets. SS Innovations has expanded its international footprint through regulatory approvals in Sri Lanka, Kenya, Indonesia, and the Philippines during the quarter, opening access to emerging healthcare markets where advanced surgical technologies are often scarce. The company continues to pursue regulatory clearance in both the United States and Europe, which could further broaden its reach and impact.
The company also recently completed the world’s longest-distance robotic cardiac telesurgery, demonstrating the capabilities of its remote surgery platform. This achievement underscores the potential for telesurgery to bridge gaps in access to specialized surgical care, particularly in underserved regions. For the healthcare industry, the expansion of telesurgery platforms could reduce the need for patient travel and enable expert surgeons to operate across borders, potentially lowering costs and improving outcomes.
The implications for investors and the medical community are substantial. SS Innovations’ strong revenue growth and expanding installed base indicate growing confidence in its technology. The company’s focus on multi-specialty procedures, including pediatric and cardiac surgeries, positions it to address a wide range of surgical needs. As regulatory approvals in major markets like the U.S. and Europe progress, the company could see even faster adoption.
For more information, visit the company’s website at www.SSInnovations.com. Further details on the company’s financials and operations are available through its investor relations materials.
